WO2001070941A3 - An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis - Google Patents
An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis Download PDFInfo
- Publication number
- WO2001070941A3 WO2001070941A3 PCT/EP2001/003272 EP0103272W WO0170941A3 WO 2001070941 A3 WO2001070941 A3 WO 2001070941A3 EP 0103272 W EP0103272 W EP 0103272W WO 0170941 A3 WO0170941 A3 WO 0170941A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- found
- multiple sclerosis
- gag
- retrovirus
- endogenous retrovirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01931543A EP1265989A2 (en) | 2000-03-21 | 2001-03-21 | An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
AU58292/01A AU5829201A (en) | 2000-03-21 | 2001-03-21 | An infective endogenous retrovirus and its association with demyelinating diseases and other diseases |
IL15186801A IL151868A0 (en) | 2000-03-21 | 2001-03-21 | An infective endogenous retrovirus and its association with demyelinating diseases and other diseases |
CA002403815A CA2403815A1 (en) | 2000-03-21 | 2001-03-21 | An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
JP2001569324A JP2004502407A (en) | 2000-03-21 | 2001-03-21 | Infectious endogenous retrovirus and its relationship to demyelinating and other diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000466 | 2000-03-21 | ||
DK200000466 | 2000-03-21 | ||
DK200000617 | 2000-04-12 | ||
DKPA200000617 | 2000-04-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001070941A2 WO2001070941A2 (en) | 2001-09-27 |
WO2001070941A3 true WO2001070941A3 (en) | 2002-08-08 |
WO2001070941A9 WO2001070941A9 (en) | 2003-05-22 |
Family
ID=26068797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/003272 WO2001070941A2 (en) | 2000-03-21 | 2001-03-21 | An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1265989A2 (en) |
JP (1) | JP2004502407A (en) |
AU (1) | AU5829201A (en) |
CA (1) | CA2403815A1 (en) |
IL (1) | IL151868A0 (en) |
WO (1) | WO2001070941A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT411262B (en) * | 2001-09-27 | 2003-11-25 | Wolff Klaus Dr | HUMAN ENDOGENIC RETROVIRUS |
EP1338606A1 (en) * | 2002-02-22 | 2003-08-27 | Magnus Von Knebel Doeberitz | Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer |
JP5504163B2 (en) * | 2008-09-18 | 2014-05-28 | 学校法人慶應義塾 | Cancer diagnosis and treatment methods |
UA119032C2 (en) * | 2012-10-02 | 2019-04-25 | Женеро Са | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650318A (en) * | 1992-04-03 | 1997-07-22 | Bio Merieux | Process and culture medium for the production of cells infected by a multiple sclerosis-associated virus |
WO1999053103A1 (en) * | 1998-04-08 | 1999-10-21 | Ms Research A/S | Diagnosis of multiple sclerosis and other demyelinating diseases |
US6001987A (en) * | 1995-08-03 | 1999-12-14 | Bio Merieux | Isolated nucleotide sequences associated with Multiple sclerosis |
-
2001
- 2001-03-21 CA CA002403815A patent/CA2403815A1/en not_active Abandoned
- 2001-03-21 WO PCT/EP2001/003272 patent/WO2001070941A2/en not_active Application Discontinuation
- 2001-03-21 AU AU58292/01A patent/AU5829201A/en not_active Abandoned
- 2001-03-21 JP JP2001569324A patent/JP2004502407A/en active Pending
- 2001-03-21 IL IL15186801A patent/IL151868A0/en unknown
- 2001-03-21 EP EP01931543A patent/EP1265989A2/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650318A (en) * | 1992-04-03 | 1997-07-22 | Bio Merieux | Process and culture medium for the production of cells infected by a multiple sclerosis-associated virus |
US6001987A (en) * | 1995-08-03 | 1999-12-14 | Bio Merieux | Isolated nucleotide sequences associated with Multiple sclerosis |
WO1999053103A1 (en) * | 1998-04-08 | 1999-10-21 | Ms Research A/S | Diagnosis of multiple sclerosis and other demyelinating diseases |
Non-Patent Citations (18)
Title |
---|
BLOND J-L ET AL: "Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family.", JOURNAL OF VIROLOGY, vol. 73, no. 2, February 1999 (1999-02-01), pages 1175 1175 - 1185, XP002902124 * |
CHRISTENSEN T ET AL: "Characterization of retroviruses from patients with multiple sclerosis.", ACTA NEUROL SCAND 1997 SUPPLEMENT 169, Denmark, pages 49 - 58, XP002902110, ISSN: 0065-1427, ISBN: 87-16-15654-4 * |
CHRISTENSEN T ET AL: "Expression of sequence variants of endogenous retrovirus RGH in particle form in multiple sclerosis", THE LANCET, vol. 352, 26 September 1998 (1998-09-26), pages 1033, XP002902107 * |
CHRISTENSEN T ET AL: "Reverse transcriptase activity and particle production in B lymphoblastoid cell lines established from lymphocytes of patients with multiple sclerosis", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 15, no. 3, 1999, pages 285 - 291, XP002902108 * |
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retovirus", XP002902111, retrieved from EMBL accession no. HE53031 * |
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902112, retrieved from EMBL accession no. HE35032 * |
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902113, retrieved from EMBL accession no. HE35033 * |
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902114, retrieved from EMBL accession no. HSU88896 * |
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902115, retrieved from EMBL accession no. HSU88897 * |
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902116, retrieved from EMBL accession no. HSU88898 * |
DATABASE EMBL LINDESKOG M ET AL: "Human endogenous retrovirus clone", XP002902118 * |
GARSON J A ET AL: "Detection of virion-associated MSRV-RNA in serum of patients with multiple sclerosis.", LANCET, vol. 351, 1 March 1998 (1998-03-01), pages 33, XP002902122 * |
GOODCHILD N L ET AL: "Spliced HERV-H endogenous retroviral sequences in human genomic DNA: evidence for amplification via retrotransposition.", VIROLOGY, vol. 206, 1995, pages 164 - 173, XP002902121 * |
KOMURIAN-PRADEL F ET AL: "Molecular cloning and characterization of MSRV-related sequences associated with retrovirus-like particles", VIROLOGY, vol. 260, 1999, pages 1 - 9, XP002902123 * |
LINDESKOG M ET AL: "Coamplification and dispersion of adjacent human endogenous retroviral HERV-H and HERV-E elements; presence of spliced hybrid transcripts in normal leukocytes.", VIROLOGY, vol. 244, 1998, pages 219 - 229, XP002902119, Retrieved from the Internet <URL:EMBL> * |
LINDESKOG M ET AL: "Isolation of a human endogenous retroviral HERV-H element with an open env reading frame.", VIROLOGY, vol. 258, 1999, pages 441 - 450, XP002902120 * |
LINDESKOG M ET AL: "Spliced human endogenous retroviral HERV-H env transcripts in T-cell leukaemia cell lines and normal leukocytes: alternative splicing pattern of HERV-H transcripts", JOURNAL OF GENERAL VIROLOGY, vol. 78, 1997, pages 2575 - 2585, XP002902117, Retrieved from the Internet <URL:EMBL> * |
MOLLER-LARSEN A ET AL: "Isolation of a retrovirus from mutiple sclerosis patients in self-generated iodixanol gredients", JOURNAL OF VIROLOGICAL METHODS, vol. 73, 1998, pages 151 - 161, XP002902109 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001070941A2 (en) | 2001-09-27 |
IL151868A0 (en) | 2003-04-10 |
JP2004502407A (en) | 2004-01-29 |
EP1265989A2 (en) | 2002-12-18 |
CA2403815A1 (en) | 2001-09-27 |
WO2001070941A9 (en) | 2003-05-22 |
AU5829201A (en) | 2001-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nakamura et al. | Redox regulation of cellular activation | |
Kajaste-Rudnitski et al. | TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-κB-responsive long terminal repeat elements | |
Dröge et al. | Functions of glutathione and glutathione disulfide in immunology and immunopathology | |
Berberian et al. | Immunoglobulin VH3 gene products: natural ligands for HIV gp120 | |
Nair et al. | Immunoregulatory effects of morphine on human lymphocytes | |
DE69737736D1 (en) | INDUCTION OF REV AND TAT-SPECIFIC CYTOTOXIC T CELLS FOR THE PREVENTION AND TREATMENT OF INFECTION BY HUMAN IMMUNODICITY VIRUS (HIV) | |
EP1714974A3 (en) | HIV-1-and HIV-2-peptides for inhibition of membranes fusion-associated events, including HIV transmission | |
Mansharamani et al. | Barrier-to-Autointegration Factor BAF Binds p55 Gagand Matrix and Is a Host Component of Human ImmunodeficiencyVirus Type 1Virions | |
Weigent et al. | The HTLV-III envelope protein contains a hexapeptide homologous to a region of interleukin-2 that binds to the interleukin-2 receptor | |
Cianciolo et al. | Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation | |
Li et al. | Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose | |
Oravecz et al. | CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV–1 strains in a T–cell line | |
Shugars et al. | Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1 | |
ES2010727A6 (en) | Monoclonal antibodies to HIV and related peptides | |
AU6745287A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
Suciu-Foca et al. | Reactivity of HTLV-transformed human T-cell lines to MHC class II antigens | |
WO2001070941A3 (en) | An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis | |
Dervillez et al. | Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV‐1 fusion inhibitory peptide C46 | |
Minato et al. | Regulation of the growth and functions of cloned murine large granular lymphocyte lines by resident macrophages. | |
Dekaban et al. | Nucleotide sequence analysis of an HTLV-I isolate from a Chilean patient with HAM/TSP | |
Xu et al. | GM-CSF restores innate, but not adaptive, immune responses in glucocorticoid-immunosuppressed human blood in vitro | |
Raj et al. | Primary plasma cell leukemia occuring in the young | |
AU2006238617B2 (en) | HIV Vif mutants | |
Gabrilovich et al. | Influence of HIV antigens on functional activity of neutrophilic granulocytes in | |
OH et al. | Partial purification and identification of an immunosuppressive factor in AIDS sera |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2403815 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151868 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 569324 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 58292/01 Country of ref document: AU Ref document number: 521762 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001931543 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018097421 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001931543 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 3/5, DRAWINGS, REPLACED BY A NEW PAGE 3/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001931543 Country of ref document: EP |